The short version: Retatrutide and tirzepatide are both incretin-based peptides, but they work differently. Tirzepatide is a dual agonist that activates the GIP and GLP-1 receptors and is a licensed medicine. Retatrutide is a triple agonist that also activates the glucagon receptor and has not been approved by any regulatory agency. Comparing the two requires understanding that one is a licensed medicine and the other is an investigational compound. Alta Peptides publishes lot-specific certificates of analysis for its research-grade retatrutide, which is the baseline standard any researcher should expect before ordering.
Search for “retatrutide vs tirzepatide” and you will find a range of comparisons that often blur the distinction between a licensed medicine and an investigational compound. Tirzepatide is a prescription medicine, marketed under brand names including Mounjaro and Zepbound. Retatrutide is not licensed. That difference is not a minor caveat. It shapes what the published data can tell you, what the regulatory status of each compound is, and how each can be legally accessed.
This guide explains the mechanisms of both compounds, what the published trial data shows, and where the comparison is limited by the differences in their development stages.
What each compound is
Tirzepatide is a dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is manufactured by Eli Lilly and is licensed in multiple jurisdictions for the treatment of type 2 diabetes and for weight management in specific patient populations.
Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors. It is also manufactured by Eli Lilly. It has reported results from several Phase 3 trials, and Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. It has not been approved by any regulatory agency for any indication. The discovery literature refers to it as LY3437943.
The difference in receptor activity is the key mechanistic distinction. Tirzepatide activates two receptors. Retatrutide activates three. The addition of glucagon receptor activity is what distinguishes retatrutide from other incretin-based compounds, and it is the subject of ongoing research into how the triple mechanism affects metabolic outcomes.
What the trial data shows
The published trial data for the two compounds comes from different phases of clinical development, which affects how the results can be compared.
The Phase 2 trial of retatrutide published in the New England Journal of Medicine in 2023 enrolled 338 adults with a BMI of 30 or higher, or a BMI of 27 to less than 30 with at least one weight-related condition. Participants received weekly subcutaneous injections of retatrutide at doses of 1mg, 4mg, 8mg, or 12mg, or placebo, for 48 weeks. The least-squares mean percentage change in body weight at 48 weeks was −8.7 percent in the 1mg group, −17.1 percent in the combined 4mg group, −22.8 percent in the combined 8mg group, and −24.2 percent in the 12mg group, compared with −2.1 percent in the placebo group.
ClinicalTrials.gov lists NCT05929066 as TRIUMPH-1, a completed Phase 3 trial evaluating retatrutide in adults without type 2 diabetes who have obesity or overweight, with sub-studies in knee osteoarthritis and obstructive sleep apnea. It evaluated the efficacy and safety of the compound over a longer treatment period than the Phase 2 study.
Eli Lilly’s investor announcement reports that the triple agonist retatrutide was successful in two additional Phase 3 trials. The announcement describes the trial results and the company’s plans for regulatory submissions.
For tirzepatide, the trial data is more extensive because the compound has completed Phase 3 development and received regulatory approval. The SURPASS and SURMOUNT trial programmes evaluated tirzepatide in type 2 diabetes and obesity, respectively. The results of those trials supported the licensing applications in multiple jurisdictions.
What the comparison does not establish is a head-to-head efficacy difference. The two compounds have not been directly compared in a randomised controlled trial, and cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints.
Regulatory status: the key difference
The most important difference between the two compounds is regulatory status.
Tirzepatide is a licensed medicine. It has received marketing authorisations from the MHRA in the UK and from the FDA in the United States. It is available by prescription for specific indications, and it is dispensed through pharmacies. The safety and efficacy data supporting the licence have been reviewed by regulators.
Retatrutide is not a licensed medicine. It has not received a marketing authorisation from any regulatory agency. It is available only through Eli Lilly’s clinical trial programme, and every other source is selling an unapproved product. Research-grade retatrutide sold for laboratory use occupies a different regulatory space, but it is not approved for human use.
That distinction matters for anyone comparing the two compounds. A licensed medicine has a body of evidence that has been reviewed by regulators. An investigational compound has a body of evidence that is still being generated and has not been reviewed for licensing purposes. The two are not equivalent.
Video: Retatrutide vs tirzepatide
This third-party video provides general context on the two compounds. It is not affiliated with Alta Peptides and is not a substitute for laboratory documentation or the published literature.
The researcher’s sourcing checklist
For researchers who need to source retatrutide as a research-grade compound, the documentation is the starting point. Here is what to check.
Lot-specific certificate of analysis. The COA should correspond to the exact lot you are buying, not a generic sample. It should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.
Complete analytical panel. A certificate that lists only a purity percentage is incomplete. The useful fields are identity by mass spectrometry, purity by HPLC, measured content, endotoxin, and sterility.
Named independent laboratory. The testing laboratory should be identified and should be a different organisation from the supplier.
Research-use-only boundary. The listing should not publish dosing, administration, or human-use content.
The Alta Peptides overview of NAD+ injections in the UK explains the regulatory context for another category of research compounds and the documentation standards that apply.
How Alta Peptides approaches research-grade documentation
Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s NAD+ and B12 pen product page is an example of how the company documents research compounds that are not peptides in the traditional sense.
The returns policy page outlines the conditions under which products can be returned and the documentation that accompanies each order.
Comparing the two compounds
The table below outlines the key differences between retatrutide and tirzepatide.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor activity | Triple agonist: GIP, GLP-1, glucagon | Dual agonist: GIP, GLP-1 |
| Regulatory status | Investigational, not approved | Licensed medicine |
| Trial phase | Phase 3 results reported; FDA submission planned for 2027 | Phase 3 complete |
| Route of access | Clinical trial or research supply | Prescription |
| Manufacturer | Eli Lilly | Eli Lilly |
| Head-to-head trial | None published | None published |
Common questions about the comparison
Is retatrutide the same as tirzepatide?
No. Retatrutide and tirzepatide are different compounds. Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors. Tirzepatide is a dual agonist that activates GIP and GLP-1 receptors. Tirzepatide is a licensed medicine. Retatrutide is an investigational compound that has not been approved by any regulatory agency.
Has retatrutide been directly compared to tirzepatide in a clinical trial?
No head-to-head trial has been published comparing the two compounds directly. Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. The two compounds have been studied in separate trial programmes.
What does the Phase 3 trial data show for retatrutide?
Eli Lilly’s investor announcement reports that retatrutide was successful in two additional Phase 3 trials. The specific efficacy figures and safety data are reported in the announcement and in the underlying trial publications.
Can I buy retatrutide as a research-grade compound in the UK?
Research-grade retatrutide is sold for laboratory use only. It is not approved for human use, and it is not a licensed medicine. Researchers should purchase only from suppliers that maintain the research-use boundary and provide analytical documentation.
What should a retatrutide COA show?
A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.
How do I verify that a COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Retatrutide is an investigational compound that has not been approved by the MHRA, the FDA, or any other regulatory agency for human use. Research peptides discussed here are sold exclusively for laboratory research use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.